By 2026, biopharma licensing deals involving Chinese originators have surpassed $130 billion in cumulative value. Pfizer and GSK have led the charge, with Chinese assets now comprising 40% of all global in-licensed molecules for major multinationals. This shift highlights a “reverse innovation” trend where the West increasingly looks East for de-risked oncology and metabolic assets.
Landmark Licensing Transactions (2025-2026)
- Pfizer & 3SBio: A record-breaking $1.25 billion upfront agreement for the bispecific SSGJ-707, with total milestones reaching $6 billion. Read the official Pfizer Press Release (July 2025).
- GSK & Hengrui Pharma: A massive $12 billion alliance covering up to 12 innovative medicines in respiratory and oncology. Detailed in the GSK Official Announcement (July 2025).
- Roche & MediLink: Expanding on their TMALIN platform deal, Roche paid $570 million in near-term payments for YL201 in January 2026.
Strategic Rationale for Cross-Border Deals
For MNCs facing patent cliffs, these biopharma licensing deals offer cost-effective, high-quality data. Chinese biotechs benefit from non-dilutive funding and global commercialization reach.
| Licensee | Licensor | Total Potential Value | Primary Source |
|---|---|---|---|
| Pfizer | 3SBio | $6.0 Billion | Pfizer.com |
| GSK | Hengrui | $12.0 Billion | GSK.com |
| Roche | MediLink | $1.8 Billion+ | MediLink News |
References
- Pfizer: Completion of SSGJ-707 Licensing Deal (July 2025)
- GSK: Multi-Asset Alliance with Hengrui Pharma (July 2025)
- MediLink: Roche Global Licensing Agreement (Jan 2026)